MAT2A and cancer: Treatment with FIDAS [25], a small molecular inhibitor of MAT2A, inhibit the expression of MAT2A mediated cancer stem cell marker and histone methylated marker in MB49-CR cells (Fig. S8E) and decreased the cell viability of MB49-CR cells with cisplatin treatment (Fig. S8F).